Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.

Inamoto, Yoshihiro; Petriček, Igor; Burns, Linda; Chhabra, Saurabh; DeFilipp, Zachariah; Hematti, Peiman; Rovó, Alicia; Schears, Raquel; Shah, Ami; Agrawal, Vaibhav; Ahmed, Aisha; Ahmed, Ibrahim; Ali, Asim; Aljurf, Mahmoud; Alkhateeb, Hassan; Beitinjaneh, Amer; Bhatt, Neel; Buchbinder, Dave; Byrne, Michael; Callander, Natalie; ... (2019). Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of blood and marrow transplantation, 25(5), e145-e154. Elsevier 10.1016/j.bbmt.2018.11.033

Text 1-s2.0-S1083879118307985-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (769kB)

Non-graft-versus-host disease (GVHD) ocular complications are generally uncommon after hematopoietic cell transplantation (HCT) but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.

Interest & Impact

Downloads

2 since deposited on 08 Oct 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item